Home > Academic Announcements > (Nov. 4) Frontiers in Pharmaceutical Sciences Lecture Series - No. 158

(Nov. 4) Frontiers in Pharmaceutical Sciences Lecture Series - No. 158

Last updated :2013-10-21

Topic: Antibody Drug Development Overview and Opportunities
Speaker: Hua Tu, Ph.D.
, President and CEO, LakePharma Inc.
Chair: Prof. Qing Li, School of Pharmaceutical Sciences, Sun Yat-sen University
Time: 2:15 PM, Monday, November 4, 2013
Venue: 125 Lecture Hall, School of Pharmaceutical Sciences, East Campus, SYSU

Brief Introduction of the speaker:

Dr. Hua Tu received his B.S. with honor in Biochemistry in 1994, and Ph.D. in Cell and Developmental Biology in 1998, at the State University of New York at Stony Brook, NY. After graduation, he joined Tularik which is based in Silicon Valley, California, as a postdoctoral fellow, and then a Scientist. In 2004 Tularik was taken by Amgen. During the 5 years as a Senior Scientist and Principle Scientist in Amgen, Dr. Tu used his expertise in protein engineering and cell-based assay to the discovery of various potent and promising lead compounds. He is professionally trained in biomedical research and especially skilled in fusion protein design, expression and production in mammalian cells. Dr. Tu is the CEO and co-founder of LakePharma, Inc. engaged in evaluation of recombinant proteins and monoclonal antibodies in inflammatory disorders and cancers. He has currently published over 20 peer-reviewed manuscripts. He is also an enthusiastic member of local academic associations, now serving as the co-chair and member of executive council of Chinese American Biopharmaceutical Society.